Fundraising FoxDementia Discovery Fund
Venture capitalLondon · Seed–Late Stage · 80 people tracked
Find your way into Dementia Discovery Fund
Each arrow is one introduction. Sign up to fill in the first one.
Ask Caroline Benn to introduce you to Christian Jung
You →Caroline · together at LoQus23 →Christian
Ask Jamie Chen to introduce you to Miles Gerson
You →Jamie · together at Viridian Therapeutics, Inc. →Miles
Ask Sam Okafor to introduce you to Laurence Barker
You →Sam · together at Therini Bio →Laurence
- Mike Ross5 people can intro you
Sign up to find every way you can get introduced to Dementia Discovery Fund
- Your email: who you already know at Dementia Discovery Fund, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Dementia Discovery Fund team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Investment thesis
SV Health Investors backs diverse entrepreneurs building breakthrough life sciences companies and treatments, aiming to transform healthcare one investment at a time. Its platform spans all healthcare sectors and stages through three dedicated teams: therapeutics/biotechnology (including a dedicated dementia strategy, the Dementia Discovery Fund), healthcare growth equity, and medtech. With more than 50 investment professionals and operating partners across Boston and London and a roughly 30-year track record, the firm seeks innovative therapeutic breakthroughs, provides growth capital and liquidity to healthcare industry leaders, and supports compelling medtech teams and technologies. It emphasizes diversity, including under-represented founders, as a driver of success.
Source: firm website, verified Sep 26, 2026.
Team · 80 people
from the firm's website
What they invest in
from 35 of 44 portfolio companiesBiotech ×29Healthtech ×22Deep Tech ×13Medical Devices ×9AI & Machine Learning ×7Digital Health ×6Data & Infrastructure ×5Longevity ×3
HQs:United States×17United Kingdom×5Australia×1
Who they back
founder profiles across 9 portfolio companiesFounding team size:solo founder×52 founders×34+ founders×1
Where their founders studiedfrom 11 founders with education data
University of Chicago ×2
What their founders studiedfrom 10 founders with field-of-study data
Life Sciences ×5Computer Science ×2Medicine ×2
Where their founders worked beforefrom 12 founders with career history
Alzheimer's Research UK ×2Pfizer ×2Rigimmune ×2UCL ×2
Investments · 44 tracked
founders shown can be your intro pathBy year:2025 · 22024 · 22023 · 72022 · 12021 · 113 dated
Bicycle Therapeutics develops precision-guided therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, designed to penetrate deep into tissues and target intractable solid tumor cancers.
BiotechHealthtechCambridge, GB
Gregory Winter(Director)inKEVIN LEE(Executive Officer, Director)inNIGEL CROCKETT(Executive Officer)inNICHOLAS KEEN(Executive Officer)SANTIAGO ARROYO(Executive Officer)inMICHAEL HANNAY(Executive Officer)
Co-investorsAhren Innovation CapitalAstellas Venture Management LLCCambridge Innovation CapitalLongwood FundRidgeback CapitalSR One Capital Management+4 more
Cerevance develops precision novel therapeutics for central nervous system disorders, particularly neurodegenerative diseases, using its proprietary NETSseq platform and machine learning to identify targets from an extensive collection of human brain tissue samples.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesBoston, US
Craig Thompson(Chief Executive Officer)inSagar Vaidya(Chief Medical Officer)inCarrie Ann Cook(Chief Business Officer)Mark Carlton(Chief Scientific Officer)inOttavio V. Vitolo(Chief Medical Officer)in
Co-investorsForesite CapitalGV (Google Ventures)SV Life SciencesDementia DiscoveryDolby Family VenturesLightstone Ventures+3 more
NeuLogiq is a research platform for clinical trials that integrates tablet-based cognitive assessments, EEG monitoring, and real-world behavioral data to measure brain function changes.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesBelfast, GB
Brian Murphy(Co-Founder & CSO)inTina(CEO)
Co-investorsClarendon Fund Managers Ltd.LifeArc Ventures
Harness Therapeutics develops disease-modifying precision therapies for hard-to-treat neurodegenerative diseases through controlled modulation of CNS targets.
BiotechHealthtech
Jan Thirkettle(CEO Director)in
Co-investorsEpidarex CapitalOno Venture Investment, Inc.SV Health Investors
Dualitas Therapeutics develops bispecific antibody therapies that pair a proprietary proximity engager arm with an antibody against a therapeutic target, using its DualScreen discovery engine to identify synergistic target combinations.
BiotechDeep TechSouth San Francisco, US
Greg Lazar, Ph.D.(Co-Founder and Chief Scientific Officer)Forbes Huang(Co-Founder, Chief Operating Officer & Chief Business Officer)inGreg Lazar(Co-Founder & Chief Scientific Officer)inRichard Murray(Executive Officer, Director)Karim Dabbagh(Chief Executive Officer, Board Member)inKarim Dabbagh, Ph.D.(Chief Executive Officer, Board Member)in
Board seatNeil Weir· per SEC Form D · $66.6M raise · filed Nov 2025
Co-investorsQiming Venture PartnersSV Health InvestorsVersant VenturesAlexandriaQiming HealthcareQiming Venture Partners USA
Alchemab operates a platform that identifies novel drug targets and therapeutics by analyzing patient antibody repertoires using deep B cell sequencing and computational analysis of samples from disease-resilient individuals.
AI & Machine LearningBiotechDeep TechHealthtech
Jane Osbourn(Chief Executive Officer)
Co-investorsRA CapitalSV Health InvestorsDCVC BioLightstone VenturesOno Venture Investment, Inc.British Business Bank+2 more
Amphista Therapeutics develops next-generation targeted protein degradation (TPD) medicines using its proprietary Targeted Glue technology, which is engineered to selectively trigger the destruction of disease-causing proteins.
BiotechCambridge, GB
Louise Modis(Chief Executive Officer)inMartin Pass(Chief Development Officer)inGiles Brown(Executive VP Drug Discovery)in
Co-investorsAdvent Life SciencesNovartis Venture FundSV Health InvestorsEuropean Investment FundForbionGilde Healthcare+2 more
Artios develops DNA damage response (DDR)-based medicines targeting patients with high unmet need cancers.
BiotechHealthtechMedical Devices
Co-investorsAndera PartnersM VenturesNovartis Venture FundPfizer Venture InvestmentsRA CapitalSofinnova Partners+3 more
AstronauTx is a biotechnology company focused on drug discovery and development for neurodegenerative and neuroinflammatory diseases, working across small molecules and biologics.
BiotechDeep TechHealthtechLongevityMedical Devices
Jane Rhodes(Chief Executive Officer)inMagnus Ivarsson(Chief Scientific Officer)inHannah Pearce(Chief Operating Officer)inMichelle L. Mellion(Chief Medical Officer)in
.jpg)
Co-investorsMPM BioImpactNovartis Venture FundSV Health InvestorsUCL Technology FundAlbionVC
Caraway Therapeutics was a preclinical biopharmaceutical company developing small-molecule therapies modulating lysosomal function to treat neurodegenerative and rare diseases.
BiotechHealthtech
Co-investorsEisai Innovation, Inc.McCarthy CapitalMRL Ventures FundSV Health InvestorsAbbVieBridge Investments+9 more
Centauri provides data-driven technology and services for U.S. health plans and health systems, turning fragmented clinical data into analytics used for risk adjustment, care coordination, quality optimization, and clinical data exchange.
Data & InfrastructureDigital HealthHealthtech
Mike McNelis(Founder)in
Co-investorsABRY PartnersSilversmith Capital PartnersSV Health Investors
Cumulus Labs provides an inference platform that consolidates production AI infrastructure (routing, caching, observability, evaluation, fine-tuning, and runtime) into a single API.
AI & Machine LearningCloud ComputingData & InfrastructureDeveloper ToolsEnterprise SoftwareSan Francisco, US
Co-investorsY CombinatorInvesting Women AngelsValor Equity PartnersBatch VenturesFounders FactoryOurCrowd+1 more
Enara Bio discovers and validates Dark Antigens from non-coding genomic regions to identify novel cancer targets, and develops first-in-class bispecific T-cell engagers against these targets through its EnTiCE platform.
BiotechDeep TechMedical Devices
George Kassiotis(Co-founder)Drew Pardoll(Co-founder)Houman Ashrafian(Co-founder)in
Co-investorsRA CapitalSV Health InvestorsPfizer VenturesSamsara BioCapitalM VenturesPfizer Venture Investments
Endlyz develops small-molecule disease-modifying therapeutics targeting the ATP13A2 and ATP10B lysosomal transporters to restore endo-lysosomal function and counter neurodegeneration.
BiotechDeep TechBoston, US
Joanna Wolak(Executive Officer, Director)inJonathan Behr(Director)John Gustofson(Director)Damian Crowther(Director)Zaven Kaprielian(Executive Officer, Director)
BoardLaurence Barker(Director)
Co-investorsOxford Science Enterprises
Evidation collects and analyzes real-world health data from millions of community members to enable clinical research and health programs across various medical conditions.
BiotechData & InfrastructureDigital HealthHealthtechSan Francisco, US
Christine Lemke(Executive Officer, Director)inDeborah Kilpatrick(Executive Officer, Director)Leslie Oley Wilberforcein
BoardDavid Fleshman(Director)Rowan Chapman(Director)in
Co-investorsAsset Management CompanyB Capital GroupB4 CapitalCross Creek AdvisorsFresco CapitalG Squared+6 more
.jpeg){kind=logo}
Leiters Health is an FDA-registered 503B outsourcing facility that produces sterile compounded preparations for hospitals, surgery centers, and ophthalmic use.
BiotechHealthtechMedical DevicesDenver, US
Co-investorsCorewell Health VenturesEscalate Capital PartnersFrazier Healthcare PartnersH.I.G. CapitalH.I.G. HealthBridge PartnersKaiser Permanente Ventures+3 more
LoQus23 Therapeutics is a drug discovery company developing treatments for triplet repeat expansion diseases such as Huntington's disease, focused on preclinical CNS and neuroscience research.
BiotechDeep TechCambridge, GB
David Reynolds(Co-founder & CEO)inCaroline Benn(Co-founder & CSO)in
Co-investorsNovartis Venture FundSV Health InvestorsForbion
Montara is a biotech company developing small-molecule therapeutics focused on neurodegeneration and diseases such as Alzheimer's.
AI & Machine LearningBiotechDeep TechSan Francisco, US
Kevan Shokat(Co-Scientific Founder & Chairman of the SAB)Thomas Südhof(Co-Scientific Founder & SAB Member)Seth Stratton(Director)Dirk Langdorf(Director)Nicholas Hertz(Executive Officer, Director)
Co-investorsBEVCDolby Family VenturesSV Health InvestorsTwo Bear CapitalKdT Ventures
Nimbus Therapeutics is a biotechnology company that designs precision small molecule medicines using a computational, multidisciplinary drug discovery approach.
AI & Machine LearningBiotechDeep TechHealthtech
Co-investorsAccess BiotechnologyAtlas VentureBain Capital Life SciencesGV (Google Ventures)Lightstone VenturesPfizer Venture Investments+4 more
Nitrase Therapeutics is a clinical-stage biopharmaceutical company using its NITROME platform to develop therapeutics based on nitrases, a class of enzymes it discovered that drive protein nitration.
BiotechHealthtechLongevity
Irene Griswold-Prenner(Founder & Chief Executive Officer)in
Co-investorsMission BiocapitalSofinnova PartnersSV Health InvestorsAbbVieMission Bay Capital
NRG Therapeutics is a biotech company developing small-molecule drugs targeting the mitochondrial permeability transition pore (mPTP) for neurodegenerative diseases such as ALS and Parkinson's.
BiotechHealthtechLongevity
Neil Miller(CEO)inRichard Rutter(CSO)inGrant Hawthorne(COO)inClaus Sundgreen(Chief Medical Officer)inPaul Thompson(CDO)in
BoardJonathan Savidge(Independent Non Executive Chair)
Co-investorsCriteria Bio VenturesNovartis Venture FundSV Health InvestorsBritish Business BankM VenturesOmega Funds
Pulmocide is a biopharmaceutical company developing inhaled therapies for difficult-to-treat respiratory diseases, currently focused on respiratory fungal infections such as pulmonary aspergillosis.
BiotechHealthtech
Pete Strong(Co-founder)Garth Rapeport(Co-founder)inKazuhiro Ito(Co-founder)inJohn Murray(Co-founder)inDavid Mantusin
Co-investorsAdjuvant CapitalAsahi Kasei Corporate Venture CapitalF-Prime CapitalJeito CapitalLongwood FundSR One Capital Management+4 more
QurAlis develops precision therapies for amyotrophic lateral sclerosis (ALS) and related neurodegenerative diseases by targeting specific disease-causing genetic drivers and molecular mechanisms.
BiotechDeep TechMedical DevicesCambridge, US
Kevin Eggan(Co-founder)inRoet(Co-founder)Woolf(Co-founder)Kasper Roet(Director, Executive Officer, Promoter)inShafique Virani(Executive Officer)inJason Brown(Mr. Brown is the Chief Financial Officer of the Issuer.)in
Co-investorsDolby Family VenturesDroia VenturesInkefMC Healthcare VenturesMission BiocapitalMitsui Global Investment+7 more
BiotechGreenville, US
Kevin Weeks(Executive Officer, Director)Katherine Warner(Executive Officer)Joshua Resnick(Director)Michael Solomon(Director)John Gustofson(Director)
Co-investorsHatteras Venture PartnersIllumina VenturesM VenturesMC Healthcare VenturesPappas CapitalSV Health Investors+2 more
Rondo Therapeutics is an immuno-oncology biopharmaceutical company developing bispecific/multispecific antibody therapeutics designed for tumor-selective targeting to treat solid tumors while sparing healthy tissue.
BiotechHealthtech
Shelley Force Aldred(Co-Founder & Chief Executive Officer)inNathan Trinklein(Co-Founder, President & CSO)inKatherine(Chief Development Officer)Thomas(Chief Medical Officer)
Co-investorsCanaan PartnersRed Tree VentureSV Health InvestorsJohnson & Johnson Innovation – JJDCNovo Holdings
Sitryx is a biotechnology company, founded in 2018, developing therapeutics with a focus on immunometabolism.
BiotechDeep TechHealthtech
Co-investorsLongwood FundOxford Science EnterprisesSofinnova PartnersSV Health Investors
Sudo Biosciences develops small molecule therapeutics for neurological and immune-mediated inflammatory conditions.
BiotechHealthtechMedical DevicesMenlo Park, US
Jim Bristol(Director)Daniel Estes(Director)inScott Byrd(Executive Officer, Director)in
Co-investorsFrazier Life SciencesMonograph Capital PartnersPICUS CAPITALSanofi VenturesSV Health InvestorsFrazier Healthcare Partners+2 more
Therini Bio is a biotechnology company developing fibrin-targeting therapeutics to treat neurological and ophthalmological diseases, leveraging scientific discoveries in neurovascular and neuroimmune mechanisms of disease.
BiotechDigital HealthHealthtechMedical DevicesSacramento, US
Katerina Akassoglou(Scientific Founder, Director of the Center for Neurovascular Brain Immunology and Professor of Neurology at UCSF and Gladstone Institutes)inKaterina Akassoglou, PhD(Scientific Founder)Leslie Schulze(Executive Officer)Tara Nickerson(Executive Officer, Director)in
BoardOlga Danilchanka(Director)inLaia Crespo-Martin(Director)
Co-investorsMRL Ventures FundSanofi VenturesSV Health InvestorsAngelini VenturesDolby Family VenturesMitsui Global Investment+2 more
TRexBio develops biologic medicines targeting inflammation in autoimmune and inflammatory diseases by decoding human tissue biology.
AI & Machine LearningBiotechDeep TechHealthtech
Johnston Erwin(Chief Executive Officer)Ali Zarrin(Chief Scientific Officer)
Co-investorsAvego BioScience CapitalDelos CapitalPfizer Venture InvestmentsSV Health InvestorsAgent CapitalPolaris Partners
Violet Labs builds software tools for engineers designing and building physical products across industries including aerospace, defense, robotics, and energy.
Data & InfrastructureDeveloper ToolsEnterprise SoftwareHardware
Lucy Hoag(Founder)in
Co-investorsFelicis VenturesMaC Venture CapitalMairs & Power VCV1 VCHopelabNorthwell Holdings+4 more
Violet provides free, personalised support for Australian families navigating end-of-life care, combining human connection and technology to offer practical guidance, emotional support, and tools for important conversations.
Digital HealthFintechHealthtechImpact & Social GoodMental HealthHaymarket, AU
BoardKate Carnell(Chairperson)
Co-investorsTechstarsHopelabNorthwell HoldingsOno Venture Investment, Inc.SemperVirens Venture CapitalThe Venture Collective+1 more
Violet provides healthcare organizations with data analytics and tools to measure and improve their ability to deliver person-centered care that considers patients' individual preferences, identities, and experiences.
Data & InfrastructureDigital HealthHealthtechNew York City, US
Gaurang Choksi(CEO and Founder)inScott Zaloom(Head of Operations)inDr. Kay Nikiforova(Head of Clinical & Research)inEliot Kristan(Head of Engineering)in
Co-investorsSeae VenturesSemperVirens Venture CapitalThe Venture CollectiveW Health Ventures Gp LlcHopelabNorthwell Holdings+2 more
Violet provides a unified API for commerce infrastructure that simplifies checkout, catalog management, and order processing for platforms and marketplaces serving multiple merchants.
B2B MarketplacesE-commerceSaaSSeattle, US
Brandon Schulz(Founder)inRhen Zabel(Executive Officer, Director, Promoter)Adam Dreiblatt(Director)
Co-investorsAlumni VenturesSeaChangeHopelabNorthwell HoldingsOno Venture Investment, Inc.Red Sea Ventures+4 more
Violet is a therapeutics company developing small molecule treatments for central nervous system diseases, using its proprietary C-to-C Engine platform to identify disease-relevant cell-to-cell interactions.
BiotechDeep TechCambridge, US
Co-investorsDementia DiscoveryOno Venture Investment, Inc.SV Health InvestorsUTEC
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
AeroCare Holdings, Inc.American WellDualitasEyeBioMisonixNitrome BiosciencesNordic Consulting PartnersSchweiger DermatologySpectrum Professional ServicesXimedica
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 3
1 IPOs · 2 acquisitionsPortfolio news
latest coverage across their companiesAlchemab · trysignalbase.com · Jul 10, 2026
Cumulus Labs · ycombinator.com · Jan 16, 2026
LoQus23 · finance.yahoo.com · Jan 6, 2026
Artios Pharma · eu-startups.com · Nov 17, 2025
Frequently asked questions
- How many investments has Dementia Discovery Fund made?
- Dementia Discovery Fund has 44 tracked investments, 3 of which have exited, including 2 dated in the last 24 months.
- What stage does Dementia Discovery Fund invest at?
- Dementia Discovery Fund invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What sectors does Dementia Discovery Fund focus on?
- Dementia Discovery Fund focuses on Biotech, Digital Health, Healthtech, IoT, Longevity, Medical Devices.
- Where is Dementia Discovery Fund located?
- Dementia Discovery Fund is headquartered in London, GB.
- Does Dementia Discovery Fund lead rounds?
- Dementia Discovery Fund has led 7 of the 12 rounds where its role is on record.
- Who does Dementia Discovery Fund co-invest with?
- Dementia Discovery Fund most often shares deals with SV Health Investors, Pfizer Venture Investments, RA Capital, among 62 tracked co-investors.
Media · Podcasts & interviews
featuring the team
Similar investors
A globally recognized venture capital firm designed to provide access to highly competitive venture deals to individual investors, consistently recognized for top-decile DPI performance and as one of the most active US venture firms.
Alumni Ventures (AV) is a venture capital firm that co-invests alongside lead VCs in startups, backing founders with capital and access to a large investor and operator community.
Brookstreet Equity Partners LLP is a London-based, family-office-originated investment manager established by shipping and principal-capital families. It deploys hybrid growth capital focused on AI-driven innovations across digital transformation, energy transition, longevity, and dual-use defence technologies.
Ahren Innovation Capital is a deep-tech investment firm that backs companies emerging at the intersection of breakthrough science and advanced technology, supported by science partners and strategic LP relationships.
LIFTT is a venture capital holding company focused on deep tech technologies, using an operational, multi-vertical approach aimed at generating impact. It works to transform scientific research into high-impact companies, accelerating the path from lab to market.